Dr. Landolt provides a remarkable blend of expertise in medicine and business that Perminova needs at this early stage of its development.
La Jolla, CA (PRWEB) February 08, 2012
Perminova, developer of web-based software for the nation’s leading cardiology centers, announced today that Cleland Landolt, MD, FACS, FACC, FACP, has joined the Perminova Board of Advisors.
Dr. Landolt brings extensive experience to the Perminova Board of Advisors as a life sciences industry executive and consultant following a successful clinical career as a cardiothoracic and vascular surgeon. In various corporate roles, he has run strategic and business development groups, and served as chief medical officer and chief operating officer. He currently provides a wide range of medical and strategic consulting services to start-up and established medical device and life sciences companies.
“A successful cardiothoracic surgeon with deep experience in the life sciences industry is a tremendous asset to Perminova as an advisor,” said Craig Collins, President and CEO of Perminova. “Dr. Landolt provides a remarkable blend of expertise in medicine and business that Perminova needs at this early stage of its development.”
Dr. Landolt served as Chief Medical Officer and Chief Operating Officer for Novellus Research Sites, a multi-site clinical research company, where he functioned as Principal Investigator or Sub-Investigator on every clinical trial. Previously, he was Chief Medical Officer and Vice President of Corporate Development for Berkeley HeartLab, Inc., part of the Celera Group, a laboratory diagnostics business. Dr. Landolt, who had primary strategic responsibility for developing emerging technologies and new ventures, also initiated strategic planning for Berkeley’s $195 million acquisition by Celera. Prior to that, he served as Vice President for Business Development of Collateral Therapeutics, Inc., an early-stage biotechnology company focused on clinical development of cardiovascular gene therapy.
Prior to transitioning to industry in 2001, Dr. Landolt had successful cardiac surgical practices on the East and West Coasts, preceded by teaching appointments at Harvard University, University of California San Francisco, and Emory University. Dr. Landolt received his undergraduate degree from Harvard College and his M.D. from Cornell University Medical College, and completed a post-doctoral research fellowship at the Cardiovascular Research Institute, San Francisco.
La Jolla, Calif.-based Perminova develops and markets web-based, cloud-based software for the nation’s leading cardiology centers. The company is pioneering healthcare’s move from outdated client-server technology to modern-and-secure cloud computing. Perminova products are electronic surgical records systems for cardiology, and they’re more robust, flexible and cost-effective than anything currently on the market. Its products improve charge-capture and efficiency, while automatically producing case reports and billing reports. Perminova seamlessly integrates with existing electronic medical records systems and deploys and upgrades easily via the web. Perminova’s architecture allows integration of medical devices and customization of robust data for medical research and clinical trials. Currently, Perminova EP is used at Mount Sinai Hospital in New York and the UC San Diego Health System.